Anti-Angiotensin type 1 receptor antibodies in chronic graft-versus-host disease

Andrada Chiron1, Jean-David Bouaziz, Maryvonnick Carmagnat

  • 11 Université Paris Diderot, Sorbonne Paris Cité; AP-HP; Hôpital Saint Louis, Paris, France. 2 Laboratoire d'Immunologie et d'Histocompatibilité, Hôpital Saint-Louis, Paris, France. 3 Service de Dermatologie, Hôpital Saint-Louis, Paris, France. 4 Laboratoire d'Immunologie, Dermatologie et Oncologie, Hôpital Saint-Louis, INSERM U976, Paris, France. 5 Service d'Hématologie-Greffe, Hôpital Saint-Louis, Paris, France. 6 Service de Pneumologie, Hôpital Saint-Louis, Paris, France. 7 INSERM U1160, Paris, France. 8 INSERM UMRS 940, Paris, France. 9 Laboratoire de Parasitologie, Hôpital Saint-Louis, Paris, France. 10 Address correspondence to: Andrada Chiron, M.D., Laboratoire d'Immunologie et d'Histocompatibilité. Hôpital Saint-Louis. 1 avenue Claude Vellefaux. 75010 Paris, France. 11 Address correspondence to: Gerard Socié, M.D., Ph.D., Service d'Hématologie-Greffe, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris, France.

Transplantation
|May 31, 2014
PubMed
Abstract

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.7K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
64.4K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K